دورية أكاديمية

Effects of nitrendipine on plasma levels of insulin and glucose in patients with essential hypertension

التفاصيل البيبلوغرافية
العنوان: Effects of nitrendipine on plasma levels of insulin and glucose in patients with essential hypertension
المؤلفون: Ricciardelli, B, Argenziano, L, Morisco, C, Monti, F, TRIMARCO, BRUNO, BARBATO, EMANUELE
المساهمون: Ricciardelli, B, Argenziano, L, Morisco, C, Monti, F, Barbato, Emanuele, Trimarco, Bruno
سنة النشر: 1997
المجموعة: IRIS Università degli Studi di Napoli Federico II
مصطلحات موضوعية: calcium channel blocking agent, cholesterol, glucose, insulin, nitrendipine, placebo, adult, article, blood pressure, cholesterol blood level, clinical article, clinical trial, controlled clinical trial, controlled study, double blind procedure, essential hypertension, female, glucose blood level, glucose metabolism, glucose tolerance, human, insulin blood level, insulin sensitivity, male, oral glucose tolerance test, priority journal, randomized controlled trial, sitting, standing, calcium antagonist
الوصف: In this randomized, double-masked, parallel-group study we assessed the effects of the calcium-channel blocker nitrendipine (10 or 20 mg) and placebo on blood pressure, glucose tolerance, and plasma insulin and cholesterol levels in 24 patients (17 men and 7 women; mean age, 44 ± 6 years) with mild-to-moderate essential hypertension. The basal insulin plasma level and the level after administration of an oral glucose load of 75 g were determined before and after the 16-week study. Patients in the nitrendipine group showed a significant decrease in sitting and standing blood pressures (from 165 ± 9.6/103 ± 6 mm Hg to 144 ± 19/91 ± 7 mm Hg and from 163 ± 7/103 ± 4 mm Hg to 144 ± 15/95 ± 7 mm Hg, respectively). Plasma glucose concentration in the nitrendipine group decreased significantly at 90 (140 ± 13 vs 183 ± 9 mg/dL, P < 0.05, before and after treatment, respectively) and 120 (121 ± 1 vs 105 ± 8 mg/dL, P < 0.01 before and after treatment, respectively) minutes after administration of the oral glucose load. Moreover, after 16 weeks (12 weeks of treatment), the nitrendipine group showed significantly reduced plasma insulin levels (68 ± 13 vs 48 ± 10 μU/mL, P < 0.05, before and after treatment, respectively) during the oral glucose tolerance test, while plasma cholesterol levels (188 ± 7 vs 184 ± 6 mg/dL, not significant, before and after treatment, respectively) did not change significantly. This study indicates that the antihypertensive effect of nitrendipine is associated with the favorable metabolic effects of improved insulin sensitivity and glucose tolerance.
نوع الوثيقة: article in journal/newspaper
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:A1997WQ36200007; volume:58; issue:3; firstpage:180; lastpage:186; numberofpages:7; journal:CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL; http://hdl.handle.net/11588/614592Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-0030994805; http://www.scopus.com/inward/record.url?eid=2-s2.0-0030994805&partnerID=40&md5=aec8b652f73b8c3a2ba285e77244af38Test
DOI: 10.1016/S0011-393X(97)80013-6
الإتاحة: https://doi.org/10.1016/S0011-393XTest(97)80013-6
http://hdl.handle.net/11588/614592Test
http://www.scopus.com/inward/record.url?eid=2-s2.0-0030994805&partnerID=40&md5=aec8b652f73b8c3a2ba285e77244af38Test
رقم الانضمام: edsbas.55D42BE4
قاعدة البيانات: BASE